Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Inflammatory Bowel Disease II: Ulcerative Colitis01:20

Inflammatory Bowel Disease II: Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Frequency of Bacteremia and the Preventive Effect of Prophylactic Antibiotics in Direct Peroral Cholangioscopy During Endoscopic Retrograde Cholangiopancreatography: A Real-life Retrospective Analysis.

The Israel Medical Association journal : IMAJ·2026
Same author

Low Serum sRAGE and MASLD Are Associated and Share a Similar Gut Microbiota Profile: A Prospective and Cross-Sectional Analysis.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

Universal submucosal dissection outperforms selective mucosal resection in early esophageal adenocarcinoma.

Endoscopy·2026
Same author

Establishing the Clinical Utility of Glucagon-Enhanced MRCP for Improved Hepatopancreatobiliary Assessment.

Journal of clinical medicine·2025
Same author

Evaluating video capsule endoscopy in diabetes mellitus: transit times, preparation adequacy, and the influence of insulin and GLP-1 receptor agonist use.

Therapeutic advances in gastrointestinal endoscopy·2025
Same author

Factors Influencing Discrepancies between Presurgery Cone-beam Computed Tomography and Intraoperative Measurements in Apical Surgery.

Journal of endodontics·2025
Same journal

Vunakizumab for IL-17A-Mediated Diseases: A Review in Psoriasis and Spondyloarthritis.

Biologics : targets & therapy·2026
Same journal

Immunological Biomarkers in Glioblastoma: Targeting T and NK Cells for Enhanced Diagnosis and Prognosis.

Biologics : targets & therapy·2026
Same journal

MicroRNA-661 Suppresses Proliferation and Migration of Pulmonary Artery Smooth Muscle Cells and Endothelial Cells by Targeting CCND2.

Biologics : targets & therapy·2026
Same journal

Vunakizumab and Acitretin for Elderly Refractory Generalized Pustular Psoriasis: A Case Report and Comprehensive Literature Review.

Biologics : targets & therapy·2026
Same journal

Rapid Resolution of Psoriasis Following Low-Dose Interleukin-2 Monotherapy: A Case Report.

Biologics : targets & therapy·2026
Same journal

Long-Term TIE2 Inhibition in a TEK-Mutated Venous Malformation: A 3-Year Clinical Experience.

Biologics : targets & therapy·2026
See all related articles

Related Experiment Video

Updated: Jun 20, 2026

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

Infliximab in ulcerative colitis.

Avi Levin1, Oren Shibolet

  • 1Gastroenterology and Liver Units, Division of Medicine, Hadassah-Hebrew University Medical center, Jerusalem, Israel.

Biologics : Targets & Therapy
|August 27, 2009
PubMed
Summary
This summary is machine-generated.

Infliximab effectively treats Crohn's disease. This review examines its controversial role in ulcerative colitis, analyzing TNF-alpha

Keywords:
anti-TNF-α antibodycrohn’s diseaseinfliximabulcerative colitis

More Related Videos

Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation
07:05

Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation

Published on: December 15, 2017

Related Experiment Videos

Last Updated: Jun 20, 2026

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation
07:05

Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation

Published on: December 15, 2017

Area of Science:

  • Gastroenterology and Immunology
  • Inflammatory Bowel Disease Research

Background:

  • Infliximab, an anti-TNF-alpha antibody, is a standard treatment for moderate to severe Crohn's disease.
  • The efficacy of infliximab for ulcerative colitis is debated.
  • Tumor necrosis factor-alpha (TNF-alpha) plays a role in ulcerative colitis pathogenesis.

Purpose of the Study:

  • To review the role of TNF-alpha in ulcerative colitis pathogenesis.
  • To assess the efficacy of infliximab in treating moderate to severe ulcerative colitis.

Main Methods:

  • Review of randomized, double-blind, placebo-controlled trials.
  • Systematic review of existing literature.
  • Analysis of TNF-alpha's role in ulcerative colitis.

Main Results:

  • Infliximab is established for Crohn's disease treatment.
  • Evidence for infliximab in ulcerative colitis requires careful evaluation of clinical trial data.
  • TNF-alpha inhibition is a key therapeutic target in IBD.

Conclusions:

  • Further investigation into infliximab's specific benefits and risks in ulcerative colitis is warranted.
  • Understanding TNF-alpha's role is crucial for optimizing IBD treatment strategies.
  • Clinical trial data guides the use of biologics like infliximab in inflammatory bowel disease.